share_log

On November 22, Oncternal Therapeutics Announced That Nasdaq Plans To Delist Its Stock On December 3, Nasdaq Classified The Company As "Public Shell," Following Its Decision To Lay Off Employees And Explore Strategic Alternatives-Filing

Benzinga ·  Nov 25, 2024 11:30

Nasdaq will file a delisting notice with the SEC. Oncternal has stated it will not appeal the decision.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 311

Recommended

Write a comment